CA2997946A1 - Use of interleukin 2 for treating spondyloarthritis - Google Patents

Use of interleukin 2 for treating spondyloarthritis Download PDF

Info

Publication number
CA2997946A1
CA2997946A1 CA2997946A CA2997946A CA2997946A1 CA 2997946 A1 CA2997946 A1 CA 2997946A1 CA 2997946 A CA2997946 A CA 2997946A CA 2997946 A CA2997946 A CA 2997946A CA 2997946 A1 CA2997946 A1 CA 2997946A1
Authority
CA
Canada
Prior art keywords
interleukin
use according
spondyloarthritis
months
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2997946A
Other languages
English (en)
French (fr)
Inventor
David Klatzmann
Francis Berenbaum
Jeremie Sellam
Bruno FAUTREL
Roberta LORENZON
Patrice CACOUB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iltoo Pharma
Assistance Publique - Hôpitaux de Paris
Sorbonne Université
Original Assignee
Iltoo Pharma
Assistance Publique - Hôpitaux de Paris
Sorbonne Université
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iltoo Pharma, Assistance Publique - Hôpitaux de Paris, Sorbonne Université filed Critical Iltoo Pharma
Publication of CA2997946A1 publication Critical patent/CA2997946A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2997946A 2015-09-10 2016-09-09 Use of interleukin 2 for treating spondyloarthritis Abandoned CA2997946A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15306383 2015-09-10
EP15306383.9 2015-09-10
PCT/EP2016/071370 WO2017042370A1 (en) 2015-09-10 2016-09-09 Use of interleukin 2 for treating spondyloarthritis

Publications (1)

Publication Number Publication Date
CA2997946A1 true CA2997946A1 (en) 2017-03-16

Family

ID=54145708

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2997946A Abandoned CA2997946A1 (en) 2015-09-10 2016-09-09 Use of interleukin 2 for treating spondyloarthritis

Country Status (6)

Country Link
US (1) US20190060407A1 (enExample)
EP (1) EP3347036A1 (enExample)
JP (1) JP2018526459A (enExample)
AU (1) AU2016319292A1 (enExample)
CA (1) CA2997946A1 (enExample)
WO (1) WO2017042370A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102777151B1 (ko) 2017-11-21 2025-03-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
EP3752178A1 (en) * 2018-02-16 2020-12-23 Iltoo Pharma Use of interleukin 2 for treating sjögren's syndrome
WO2020007937A1 (en) * 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
KR20210039403A (ko) 2018-08-01 2021-04-09 타리스 바이오메디컬 엘엘씨 트로스피움을 사용한 과민성 방광의 치료 방법
CN115362168A (zh) 2020-01-14 2022-11-18 辛德凯因股份有限公司 偏向化il2突变蛋白方法和组合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3443979B2 (en) * 2011-03-11 2026-05-20 Assistance Publique - Hôpitaux De Paris IL-2 DOSAGE REGIMEN FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS
CN104189892A (zh) * 2014-08-22 2014-12-10 北京大学人民医院 低剂量白细胞介素2在免疫相关性疾病治疗中的应用

Also Published As

Publication number Publication date
AU2016319292A1 (en) 2018-04-12
WO2017042370A1 (en) 2017-03-16
EP3347036A1 (en) 2018-07-18
JP2018526459A (ja) 2018-09-13
US20190060407A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
JP7561893B2 (ja) 自己免疫関連障害または炎症性障害の治療のための低用量ｉｌ－２の使用
US20210038691A1 (en) Use of low dose il-2 for treating autoimmune-related or inflammatory
WO2017042370A1 (en) Use of interleukin 2 for treating spondyloarthritis
US11534479B2 (en) Use of interleukin 2 for treating Sjögren's syndrome
JP2022539785A (ja) ＴＡＣＩ－Ｆｃ融合タンパク質及びその用途
US4946674A (en) Process for treatment of rheumatic diseases
US20260108530A1 (en) Methods for the treatment of psoriatic arthritis
ES2309299T3 (es) Tratamiento de la artritis reumatoide usando imatinib.
Karanikolas et al. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis.
KR20070012801A (ko) 인터페론-타우에 의한 치료를 최적화하는 방법
WO2020007937A1 (en) Use of interleukin-2 for treating systemic sclerosis
US20100234277A1 (en) Coadministration of alpha-fetoprotein and a disease modifying anti-rheumatic drug for treating inflammatory arthritic disease
RU2814988C2 (ru) Слитый белок taci-fc и его применение
US20230338356A1 (en) Treatment of autoimmune skin disease
CN117561076A (zh) 使用ilt7结合蛋白治疗自体免疫病症的方法
WO2000035472A2 (en) Cytokine combination therapy
JP5699030B2 (ja) エタネルセプトを含む線維筋痛症の治療剤
AU2022414070A1 (en) Dosing regimens for selective treg stimulator rur20kd-il-2 and related compositions
WO2005049068A1 (en) Use of interferon tau for the treatment of obesity and for promotion of weight loss
Williams et al. Chronic Graft-Versus-Host Disease.
MEMON et al. EFFICACY OF CYCLOSPORINE IN 36 PATIENTS WITH RHEUMATOID ARTHRITIS
HK1072192B (en) Treatment of rheumatoid arthritis using imatinib

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20220309